Clinical Trial Detail

NCT ID NCT04410796
Title Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Osimertinib + Pemetrexed Disodium

Osimertinib

Age Groups: senior adult

No variant requirements are available.